Table 1 Clinicopathologic and demographic characteristics of recipients, donors and transplant compared between T1DM und T2DM

Age at onset of diabetes mellitus, years

15.9 +/−  9.1

28.6 +/−  10.9

41.2 +/−  12.4

< 0.01

Recipient age, years

42.3+/−  8.4

48.7+/−  10.6

61.5+/− 8.6

< 0.01

Recipient gender

0.04

 Male

49 (55.1%)

8 (66.7%)

21 (80.8%)

 Female

40 (44.9%)

4 (33.3%)

5 (19.2%)

Recipient BMI (kg/m2)

24.8 +/− 4.1

26.4 +/− 4.9

28.6 +/− 3.1

< 0.01

Duration of Diabetes mellitus, years

27.6 +/− 7.9

18.7 +/− 9.8

18.9 +/− 8.9

< 0.01

Insulin amount, IU/d

47.9 +/− 22.3

37.1 +/− 18.1

42.1 +/− 19.3

n.s.

Donor age, years

23.9 +/−  11.7

17.3 +/−  12.1

59.7 +/−  17.4

< 0.01

Donor BMI (kg/m2)

22.5 +/− 3.5

22.1 +/− 2.6

25.4 +/−  3.5

< 0.01

Donor, gender

n.s.

Male

56 (62.9%)

4 (33.3%)

12 (46.2%)

Female

33 (37.1%)

8 (66.7%)

14 (53.8%)

Donor- Cause of Death, CVA %

26 (29.2%)

5 (41.7%)

15 (57.7%)

0.03

CIT Pancreas, hours

10.7 +/− 2.6

10.9 +/− 2.4

N.A.

n.s.

CIT kidney, hours

11.2 +/− 3.2

11.7 +/− 2.8

11.3 +/− 4.9

n.s.

Waiting time, months

7.8 +/− 10.4

15.1 +/− 16.4

22.3 +/−  28.4

0.01

Petransplant dialysis duration, months

31.54 +/−35.19

40.58 +/−  23.3

88.28 +/−  49.1

< 0.01

Pre-emptive transplant

22 (24.7%)

0 (0%)

2 (7.7%)

0.03

Systolic blood pressure, mmHG

134 +/− 17

138 +/− 21

141 +/−  18

0.04

Diastolic blood pressure, mmHG

76 +/− 8

79 +/− 11

82 +/− 11

0.03

HbA1c pretransplantation,%

7.9 +/− 1.7

6.6 +/− 1.4

6.7 +/− 0.9

0.01

C-Peptid, ng/ml

0.15 +/− 0.4

3.2 +/− 1.1

–

< 0.01

Total cholesterol,

5.2 +/− 1.4

5.6 +/−  0.8

4.9 +/−  1.6

n.s.

Triglyceride,

1.9 +/− 1.1

2.5 +/− 1.7

2.6 /−  1.2

0.04

LDL- cholesterol,

2.8 +/− 0.9

2.9 +/− 1.1

2.8 +/− 1.4

n.s.

HDL- cholesterol,

1.5 +/− 0.4

1.2 +/− 0.3

1.2 +/−  0.4

0.02

Arterial obstructive disease

0.04

 Yes

15 (16.9%)

2 (16.7%)

10 (40%)

 No

74 (83.1%)

10 (83.3%)

15 (60%)

Coronary heart disease

< 0.01

 Yes

23 (25.8%)

6 (50%)

19 (73.1%)

 No

66 (74.2%)

6 (50%)

7 (26.9%)

CABG/stent

< 0.01

 Yes

15 (83.1%)

4 (33.3%)

16 (64%)

 No

74 (16.9%)

8 (66.7%)

9 (36%)

Retinopathy

< 0.01

 Yes

78 (87.6%)

8 (66.7%)

10 (38.5%)

 No

11 (12.4%)

4 (33.3%)

16 (61.5%)

Neuropathy

n.s.

 Yes

55 (73.3%)

9 (75%)

12 (46.2%)

 No

34 (38.9%)

3 (25%)

14 (53.8%)

Nephropathy

N.A.

 Yes

89 (100%)

12 (100%)

26 (100%)

 No

0 (0%)

0 (0%)

0 (0%)

Number of antihypertensive drugs

n.s.

 0

14 (15.7%)

3 (25%)

9 (34.6%)

 1

6 (6.7%)

1 (8.3%)

2 (7.7%)

 2

14 (15.7%)

2 (16.7%)

6 (23.1%)

 3

24 (27%)

2 (16.7%)

5 (19.2%)

 4

18 (20.2%)

1 (8.3%)

2 (7.7%)

  > 4

13 (14.6%)

3 (25%)

2 (7.7%)

Panel reactive antibodies (PRA), %

75 (85.2%)

12 (100%)

19 (73.1%)

n.s.

0

10 (11.4%

0

5 (19.2%)

1–20 > 20

3 (3.4%)

0

2 (7.7%)

HLA-DR mismatch; n

1.3 +/− 0.5

1.1 +/− 0.4

2.3 +/− 1.4

< 0.01

CNI

n.s.

 Tacrolimus

85 (95.5%)

12 (100%)

25 (96.2%)

 Cyclosporin

4 (4.5%)

0 (0%)

1 (4.5%)

Induction Therapy

< 0.01

 ALG/ATG

63 (70.8%)

11 (91.7%)

4 (15.4%)

 IL2-RA

19 (21.3%)

0 (0%)

12 (46.2%)

 None

7 (7.9%)

1 (8.3%)

10 (38.5%)

AP drug

0.01

 MMF

72 (80.9%)

11 (91.7%)

22 (84.6%)

 SRL

13 (14.6%)

1 (8.3%)

0

 Multiple

3 (3.4%)

0

0

 NONE

1 (0.8%)

0

4 (15.4%)